Former CEO of OPK Biotech LLC which developed the first approved HBOC for human use. Mr. Kowalski is a veteran of the investment banking industry, holding numerous senior positions with firms such as Bankers Trust, where he was Vice Chairman of Europe, the Middle East and Africa, Building offices in Russia, Eastern Europe, Turkey and Israel.  He was global head of emerging market investment banking for Credit Suisse and CEO of Rose Square Capital an advisory firm with offices in London, Kiev, and Moscow.  Mr. Kowalksi was chairman of the largest bank by capital in Russia. Mr. Kowalski is on the board of The Rollicking Crew University of Michigan Endowed Scholarship Fund, Shorts International and a member of the Clinton Global Initiative, Prague Society and Global Panel. Mr. Kowalski holds a BA in Economics from the University of Michigan.



Mr. Zafirelis has more than 25 years of CEO experience in private and public companies, including start-up ventures and turnaround situations. He has an extensive background in the biotech and medical device industries, with broad knowledge of oxygen therapeutic and cardiovascular products. Mr. Zafirelis was part of the original team at Biopure that led the development and approval of Oxyglobin®, the veterinary oxygen carrier, by the FDA and EMA. He has led two cardiac device companies, Medquest and Cardiacassist, and has substantial experience in the approval of new biologics and devices with regulators worldwide. Mr. Zafirelis has an MS in Chemistry and an MBA from the University of Southern California.



Mr. Serov has over 20 years of experience in the Investment Banking industry. He spent most of his career in London running such groups as capital markets, structured products, and advisory.  Mr. Serov has worked at Bankers Trust, Rose Square Capital, Dresdner Kleinwort Benson, and Renaissance Capital.  Before joining Hemoglobin Oxygen Therapeutics, he was heading up coverage for corporate clients and financial institutions at Sberbank, the largest Russian bank. Mr. Serov has a BA in Mathematics and Economics from Connecticut College.



Mr. Leibensperger has 18 years of experience in Biopharmaceutical Manufacturing and Operations Management. He was an original team member with Biopure Corp. that helped bring Oxyglobin® and Hemopure® production to full scale and an integral part of achieving FDA and EMA GMP approval for manufacturing facilities. Bruce has had direct responsibilities for addressing FDA, EMA, and MHRA regulatory agencies. Most recently served as a Plant Director at OPK Biotech LLC and was responsible for restart operations. Employing Lean Manufacturing principles, the OPK Biotech Souderton Facility was fully operational ahead of schedule and gained VMD approval for veterinary product marketing. Previously, he served as a Biomaterials Manufacturing Manager at Globus Medical Inc. where he managed restructuring of department personnel and multiple production lines including polymer-based bone void implants, and spinal implant devices that gained both FDA and EU marketing approval. Mr. Leibensperger has a B.S. degree in Biology from Susquehanna University.



Brian Dawson has over 25 years experience working with the development and commercialization of Hemopure and Oxyglobin. In this position with Hemoglobin Oxygen Therapeutics LLC, Mr. Dawson is responsible for the transition of the manufacturing process and components from the Cambridge, MA manufacturing facility to the Souderton, PA manufacturing facility. Mr. Dawson started his career with Biopure in 1989 and held several positions in manufacturing operations offering broad qualifications in all facets of production, maintenance, calibration, supply chain, process engineering, validation, environmental control, anaerobic aseptic filling, packaging, microbiology and capacity management. The scope of Mr. Dawson’s experience encompasses preclinical research and development phase through product approval and marketing.  He is successful in streamlining production processes, accelerating performance, reducing costs, and meeting time-critical industry demands. Brian was Director of Operations for both Biopure and OPK Biotech LLC, and has a BA from North Adams State College (Massachusetts College of Liberal Arts).


HbO2 Therapeutics LLC  - All Rights Reserved